Top Story

Anemia treatment not beneficial after brain injury

August 27, 2014

Two frequently used anemia treatments did not improve short-term neurocognitive outcomes in patients who experienced a traumatic brain injury, according to results of a randomized trial.

Neither treatment with erythropoietin nor maintaining hemoglobin concentration of at least 10 g/dL offered no benefit in neurological recovery. In fact the transfusion threshold of 10 g/dL was associated with a higher incidence of adverse events.

FDA approvals

FDA expands approval of Promacta

August 26, 2014
The FDA today expanded the improved indications for eltrombopag to include treatment of patients with severe aplastic anemia who demonstrated an insufficient response to…
figure In the Journals

Aspirin reduced risk for recurrent VTE

August 25, 2014
Aspirin after anticoagulation reduced the risk for recurrent venous thromboembolism by more than one-third in patients with a first unprovoked VTE, according to new…
FDA approvals

FDA approves Eliquis for treatment of DVT, PE

August 21, 2014
The FDA has approved a supplemental new drug application for apixaban, an oral selective Factor Xa inhibitor, for the treatment of deep vein thrombosis and pulmonary…
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME CNE

Treatment Decision-Making through the Spectrum of MDS: Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

8/20/2014
MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

figure In the Journals

Anemia treatment not beneficial after brain injury

August 27, 2014
Two frequently used anemia treatments did not improve short-term neurocognitive outcomes in patients who experienced a traumatic brain injury…
FDA approvals

FDA expands approval of Promacta

August 26, 2014
The FDA today expanded the improved indications for eltrombopag to include treatment of patients with severe aplastic anemia who demonstrated an…
figure In the Journals

Aspirin reduced risk for recurrent VTE

August 25, 2014
Aspirin after anticoagulation reduced the risk for recurrent venous thromboembolism by more than one-third in patients with a first unprovoked VTE…
FDA approvals

FDA approves Eliquis for treatment of DVT, PE

August 21, 2014
The FDA has approved a supplemental new drug application for apixaban, an oral selective Factor Xa inhibitor, for the treatment of deep vein…
figure In the Journals

Regular transfusions reduced stroke recurrence in pediatric sickle cell anemia

August 20, 2014
Children with sickle cell anemia who underwent regular blood-transfusion therapy experienced fewer recurrences of cerebral infarct, according to…
In the Journals

Newborn screening identified higher incidence of SCID

August 19, 2014
Newborn screening for severe combined immunodeficiency detected the condition in 1 out of every 58,000 births.This population-based rate was higher…
In the Journals

Adolescents, young adults with sickle cell disease have higher rates of chlamydia

August 19, 2014
Adolescents and young adults with sickle cell disease are more likely to have asymptomatic chlamydia compared with adolescents without the disease…
In the Journals

Meta-analysis: Bivalirudin vs. heparin increases risk for MI, stent thrombosis, decreases bleeding

August 15, 2014
Results from a new meta-analysis have found that an anticoagulation regimen of bivalirudin vs. heparin increases the rate of MI and stent thrombosis…
In the Journals

Persistently negative D-dimers associated with low VTE recurrence

August 13, 2014
Patients with persistently negative D-dimer measurements demonstrated a low risk for venous thromboembolism recurrence and were able to safety…
In the Journals Perspective

Modified blood stem cell transplant reversed sickle cell disease in adults

HemOnc Today, August 10, 2014
Adults with sickle cell phenotype achieved a high rate of stable mixed-donor chimerism and disease reversal after they underwent non-myeloablative…
More Headlines »